Browse the evidence

Insulin stimulated S473 phosphorylation of Akt1 was increased by approximately 25% in a high-fat diet.

High-fat diets can enhance insulin signaling through Akt1, which may have implications for metabolic health.

Akt Ser(473) phosphorylation was increased 1.8-fold after endurance exercise but was unchanged after resistance exercise.

Endurance exercise significantly activates Akt signaling in trained individuals.

Phosphorylation of AS160 and filamin A increased 2.0-fold and 4.9-fold, respectively, after endurance exercise but not after resistance exercise.

Endurance exercise enhances the phosphorylation of key signaling proteins in muscle.

Fatty acid oxidation by muscle is limited, especially at the exercise intensities sustained by athletes during training and competition.

Athletes may need to consider nutritional strategies to enhance fat oxidation during high-intensity exercise.

Improvements in HOMA and Matsuda index did not differ significantly between the HLF and HLC diets.

Both diets can be considered equally effective for improving certain aspects of insulin sensitivity.

Differences in fat availability and utilization during steady-state exercise had little effect on the time taken to complete a 600 kJ time-trial.

Fat availability may not influence performance in short-duration high-intensity efforts.

Dietary glycemic index does not influence the adaptation of resting energy expenditure during weight loss.

Practitioners should note that dietary glycemic index may not be a significant factor in managing resting energy expenditure during weight loss.

Measured resting energy expenditure (mREE) was significantly lower than predicted resting energy expenditure (pREE) at both 12 weeks and 17 weeks.

This indicates that weight loss leads to a significant decrease in energy expenditure, which should be considered in weight management strategies.

Body composition changes did not differ significantly by dietary fat or glycemic index.

This suggests that dietary fat and glycemic index may not be critical factors in body composition changes during weight loss.

Neither Ins-30 nor genotype pattern modified the effect of diet on 12-month weight loss.

Individual factors like insulin secretion and genotype may not need to be considered when choosing between these diets for weight loss.

Higher Genetic Risk Score (GRS) relates to smaller year one change in waist circumference adjusted for body mass index (WCadjBMI) in lifestyle intervention arms.

Practitioners should consider genetic risk factors when designing weight loss interventions, as they may influence outcomes.

Each weighted risk allele in the GRS contributes to a 0.06 cm higher waist circumference at year 1 for individuals with an initial BMI of 34 and a year 1 reduction in BMI of 2.5.

Understanding the genetic contribution to waist circumference can help tailor interventions for individuals.

There are three broadly different subtypes of vegan diets: vegan (general), raw food vegan, and whole food vegan.

Understanding the different subtypes of vegan diets can help practitioners tailor dietary advice.

Obesity is influenced by biological, genetic, behavioural, and environmental factors.

Practitioners should consider multiple factors when addressing obesity.

Neither High Quality nor High Adherence alone were significantly different than the Low Quality/Low Adherence subgroups.

Focus on both dietary quality and adherence rather than either alone for weight loss strategies.

In China, there was no significant association between white rice intake and diabetes risk (HR: 1.05; 95% CI: 0.78-1.41, p for trend = 0.38).

Dietary recommendations regarding white rice may differ in China compared to other regions due to the lack of associated diabetes risk.

GLP-1 receptor agonists (GLP-1RAs) have adverse events associated with their increased use.

Practitioners should be aware of the potential adverse events when prescribing GLP-1RAs.

Weight loss magnitude was lower in patients taking GLP-1 RAs compared to postbariatric patients (29.9 kg vs 47.2 kg).

Understanding the differences in weight loss can help tailor interventions for patients seeking body contouring.

GLP-1RAs users demonstrated significantly reduced risks of poor functional outcomes (odds ratio 0.37, 95% CI 0.21-0.66).

Using GLP-1 receptor agonists may enhance functional recovery in patients post-treatment.

GLP-1RAs users had significantly reduced risks of new subarachnoid hemorrhage (odds ratio 0.39, 95% CI 0.27-0.56).

GLP-1 receptor agonists may lower the risk of subarachnoid hemorrhage in treated patients.

GLP-1 agonists may decrease sexual desire through increased serotonergic activity at the 5-HT2C receptor.

Clinicians should consider the potential impact of GLP-1 agonists on sexual desire when prescribing these medications.

The effects of GLP-1 agonists on sexual desire may be overlooked due to competing influences.

Awareness of these competing influences is crucial for healthcare providers managing patients on GLP-1 agonists.

Systematic measurement of sexual desire should be prioritized in future research on GLP-1 agonists.

Researchers should include sexual desire as a key outcome in studies involving GLP-1 agonists.

Gastrointestinal complaints were common but did not significantly influence satisfaction ratings or decisions to continue treatment.

Practitioners should note that while gastrointestinal side effects are common, they may not deter patients from continuing treatment if weight loss is achieved.